Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous serum tears (AST) are a biological product derived from a patient's own blood, processed to create eye drops that resemble natural tears. They contain essential components such as epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), vitamins, and nutrients. These components support epithelial cell homeostasis, growth, and migration, and promote corneal nerve regeneration. AST are primarily used as a therapeutic alternative for severe dry eye disease (DED), especially in cases refractory to conventional treatments or secondary to systemic conditions like Sjögren's syndrome and ocular graft-versus-host disease (GvHD), as well as ocular pathologies such as neurotrophic keratitis, chemical burns, and ocular cicatricial pemphigoid. They are often considered a third-line treatment option for severe DED.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous serum tears.